Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0001104659-25-028313·Scinai Immunotherapeutics Ltd.
Schedule 13G ownership disclosure
Scinai Immunotherapeutics Ltd.
American Depository Shares, each representing 4,000 Ordinary Shares, no par value · CUSIP: 09073Q203
Event date: 2025-03-24
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- YA II PN, Ltd.
Shares: 93,274.00 · Class: 9.9%
- YA Global Investments II (U.S.), LP
Shares: 93,274.00 · Class: 9.9%
- Yorkville Advisors Global, LP
Shares: 93,274.00 · Class: 9.9%
- Yorkville Advisors Global II, LLC
Shares: 93,274.00 · Class: 9.9%
- YAII GP, LP
Shares: 93,274.00 · Class: 9.9%
- YAII GP II, LLC
Shares: 93,274.00 · Class: 9.9%
- Mark Angelo
Shares: 93,274.00 · Class: 9.9%
- SC-Sigma Global Partners, LP
Shares: 93,274.00 · Class: 9.9%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-028313
- Form type
- SCHEDULE 13G
- Filer
- Scinai Immunotherapeutics Ltd.
- CIK
- CIK 1611747
- Filed
- Mar 26, 2025
- Reporting period
- Mar 24, 2025
- Description
- Schedule 13G beneficial ownership